The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Novel therapies for myelofibrosis
Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, highlights novel approaches investigated in the treatment of myelofibrosis at EHA 2020, these include KRT-232, an MDM2 inhibitor, as well as pelabresib (CPI-0610), a BET inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
